Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Renuka V. Iyer

Oncology

Roswell Park Cancer Institute

Elm And Carlton St,

Buffalo, NY

Clinical Trials:Currently Recruiting for 1 Trial

Offers Telehealth

Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Roswell Park Cancer Institute

Elm And Carlton St,

Buffalo, NY

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Renuka Iyer is an Oncologist in Buffalo, New York. Dr. Iyer is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). Her top areas of expertise are Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Pancreatic Islet Cell Tumor, and Tissue Biopsy.

Her clinical research consists of co-authoring 109 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in NY

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Blue Cross Blue Shield

Cigna

Highmark

Humana

HMO
INDEMNITY
POS
PPO

Independent Health

Medicaid

OTHER MEDICAID
STATE MEDICAID

MVP Health

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 5 Less Insurance Carriers -

Locations

ROSWELL PARK CANCER INSTITUTE
Elm And Carlton St, Buffalo, NY 14263

Call: 716-845-2300

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide

Study Phase: Phase 2/Phase 3

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Enrollment Status: Active_not_recruiting

Publish Date: October 08, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Cabozantinib S-malate

Study Phase: Phase 3

A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug

Study Drugs: Carboplatin, Paclitaxel, Pevonedistat

Study Phase: Phase 2

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Other

Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib

Study Phase: Phase 2

A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Enrollment Status: Completed

Publish Date: September 11, 2025

Intervention Type: Biological, Drug

Study Drugs: Incomplete Freund's Adjuvant, Octreotide, Sargramostim, SurVaxM Survivin Long Peptide Vaccine

Study Phase: Phase 1

A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Biological, Drug

Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab

Study Phase: Phase 2

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Enrollment Status: Completed

Publish Date: June 11, 2025

Intervention Type: Drug

Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel

Study Phase: Phase 3

A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)

Enrollment Status: Active_not_recruiting

Publish Date: June 04, 2025

Intervention Type: Other, Drug, Biological

Study Drugs: Pembrolizumab, Sorafenib Tosylate

Study Phase: Phase 1/Phase 2

A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers

Enrollment Status: Active_not_recruiting

Publish Date: May 23, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Atezolizumab, Cobimetinib, Varlilumab

Study Phase: Phase 2

Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin

Enrollment Status: Terminated

Publish Date: January 30, 2025

Intervention Type: Drug, Procedure

Study Drugs: Fluorouracil, Leucovorin, Liposomal Irinotecan

Study Phase: Phase 2

A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Enrollment Status: Terminated

Publish Date: June 05, 2024

Intervention Type: Drug, Other

Study Drugs: Atezolizumab, Bevacizumab

Study Phase: Phase 2

An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine Tumors

Enrollment Status: No_longer_available

Publish Date: April 12, 2024

Intervention Type: Drug

Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors

Enrollment Status: Completed

Publish Date: December 26, 2023

Intervention Type: Other, Drug

Study Drug: Nintedanib

Study Phase: Phase 2

A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: July 25, 2022

Intervention Type: Drug, Other

Study Phase: Phase 1

Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC

Enrollment Status: Completed

Publish Date: July 25, 2022

Intervention Type: Other, Drug

Study Phase: Not Applicable

A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm

Enrollment Status: Completed

Publish Date: December 10, 2020

Intervention Type: Drug

Study Phase: Phase 1

Multicenter Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma

Enrollment Status: Completed

Publish Date: October 28, 2020

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

View 16 Less Clinical Trials

109 Total Publications

Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 10, 2025

View All 109 Publications

Similar Doctors

Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Christos Fountzilas

Oncology

Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Christos Fountzilas

Oncology

Roswell Park Cancer Institute

Elm And Carlton St,

Buffalo, NY

(0.1 miles away)

716-845-2300

Languages Spoken:

English

See accepted insurances

Christos Fountzilas is an Oncologist in Buffalo, New York. Dr. Fountzilas is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, and Stomach Cancer.

Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Anuradha Krishnamurthy

Oncology

Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Anuradha Krishnamurthy

Oncology

Roswell Park Cancer Institute

Elm And Carlton St,

Buffalo, NY

(0.1 miles away)

716-845-2300

Languages Spoken:

English

See accepted insurances

Anuradha Krishnamurthy is an Oncologist in Buffalo, New York. Dr. Krishnamurthy is rated as an Advanced provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Neuroendocrine Tumor, and Familial Pancreatic Cancer.

Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Devinderpal S. Randhawa

Hematology Oncology | Hematology | Oncology

Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Devinderpal S. Randhawa

Hematology Oncology | Hematology | Oncology

Erie County Medical Center Corporation

462 Grider St,

Buffalo, NY

(2.0 miles away)

716-898-3000

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Devinderpal Randhawa is a Hematologist Oncology specialist and a Hematologist in Buffalo, New York. Dr. Randhawa is rated as an Advanced provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Lynch Syndrome, and Colorectal Cancer. Dr. Randhawa is currently accepting new patients.

VIEW MORE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR (GEP-NET) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Iyer's expertise for a condition

ConditionClose